US Revocation Of Hong Kong Special Status To Rain On Biotech IPO Parade?
Or Might Stability Bring Investor Confidence?
Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.
